Improvement in Disease Activity in Refractory Juvenile Dermatomyositis Following Abatacept Therapy
Abstract
This open‐label, 24‐week study was conducted to evaluate the safety and efficacy of abatacept in patients with refractory juvenile dermatomyositis (DM).
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jun 07, 2023
- Source ID
- 10.1002/art.42450
Entities
People
- Alison Ehrlich
- Derek Jones
- Gulnara Mamyrova
- Hanna Kim
- Kathleen A. Brindle
- Lisa G. Rider
- Olcay Y Jones
- Robert Sheets
- Rodolfo Curiel
- Shahriar Haji‐momenian
- The Abatacept In Dermatomyositis (aid) Trial Investigators
- William Nguyen
Organizations
- George Washington University
- George Washington University Medical School
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- National Institute of Environmental Health Sciences
- University of California